Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of NSC228155 in preparation of drug for preventing and treating chronic renal fibrosis

A 1. NSC228155, the technology of renal fibrosis, applied in the field of medicine, can solve the problem of lack of effective means for chronic kidney disease

Active Publication Date: 2020-07-03
NANJING CHILDRENS HOSPITAL
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For decades, although people have extensively explored the pathogenesis and intervention strategies of CKD, so far, there is still a lack of effective means for the prevention and treatment of chronic kidney disease. A considerable number of CKD patients eventually develop into end-stage renal disease, requiring expensive Renal replacement therapy brings great burden to family and society
There are no reports of NSC228155 being used in the treatment of chronic renal fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of NSC228155 in preparation of drug for preventing and treating chronic renal fibrosis
  • Application of NSC228155 in preparation of drug for preventing and treating chronic renal fibrosis
  • Application of NSC228155 in preparation of drug for preventing and treating chronic renal fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 The therapeutic dose of NSC228155 has no toxic side effects on mice and cells

[0046] 1 Experimental materials and methods

[0047] 1) Administration, feeding and sampling of mice

[0048] The C57BL / 6 species male mice used in the present invention (7 weeks old at the time of purchase, body weight 20-24g) were purchased from the Experimental Animal Center of Nanjing Medical University, raised in an SPF level barrier environment of the Experimental Animal Center of Nanjing Medical University, and the animals were free to eat , maintaining a circadian rhythm of 12 hours of light and 12 hours of darkness. Laboratory temperature: 20-25°C, humidity 50±5%. After one week of adaptive feeding, the mice were randomly divided into control group (n=10) and NSC228155 group (n=10).

[0049] The present invention uses NSC228155 (purity≥99%) purchased from Selleck Company. Dilute to 0.25 mg / ml with vehicle (5% DMSO, 35% PEG-300, 65% sterile saline) before administration...

Embodiment 2

[0058] Example 2 NSC228155 improves renal fibrosis in the UUO model

[0059] 1 Experimental materials

[0060] The C57BL / 6 species mouse and NSC228155 (purity ≥ 99%) used in the present invention are from the same source as in Example 1.

[0061] 2 Experimental methods

[0062] 2.1 Animal administration, modeling and sampling

[0063] Twenty male C57BL / 6 mice (7 weeks old at the time of purchase, weighing 20-24 g) were raised in an SPF-grade barrier environment in the Experimental Animal Center of Nanjing Medical University. The animals ate freely and maintained a circadian rhythm of 12 hours of light and 12 hours of darkness. Laboratory temperature: 20-25°C, humidity 50±5%. After one week of adaptive feeding, the mice were randomly divided into control group (n=10) and NSC228155 group (n=10). After grouping, the mice in the control group and the mice in the NSC228155 group were injected intraperitoneally with vehicle or NSC228155 once a day, for a total of 8 injections. ...

Embodiment 3

[0074] Example 3 NSC228155 reduces the expression level of fibrosis indicators in kidney tissue

[0075] 1. Experimental materials and methods

[0076] The source and use of mice and NSC228155 were as described in Example 2. The establishment method and tissue collection of the mouse UUO model are the same as in Example 2.

[0077] 1) RT-PCR

[0078] After RNAiso reagent from Takara company was used to extract the RNA in the sample according to the instructions, the RNA was reverse-transcribed into cDNA using the reverse transcription kit from Vazyme company, and SYBR green PCR mix combined with corresponding primers was used for RT-PCR detection.

[0079] 2) Statistical analysis

[0080] Histograms represent data using mean ± SEM. Analysis of variance (ANOVA) was used for comparison between multiple groups, and T test was used for data comparison between two groups. P<0.05 was regarded as statistically significant.

[0081] 2. Experimental results

[0082] In order to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of NSC228155 in treating chronic renal interstitial fibrosis, and particularly relates to application of the NSC228155 in treating the chronic renal interstitial fibrosis by resisting inflammation and protecting renal tubular epithelial cells (RTECs). The NSC228155 can relieve pathological change of a chronic renal interstitial fibrosis mouse model, reduce the expression level of fibrosis factors of renal tissue of a mouse, reduce inflammatory reaction of renal tissue and fibroblasts, protect the RTECs in the fibrosis model and reverse the transdifferentiation effect of the RTECs.

Description

technical field [0001] The invention belongs to the field of medicine, and specifically relates to the use of compound NSC228155 in the preparation of drugs for preventing and treating chronic renal fibrosis. Background technique [0002] Chronic kidney disease (chronic kidney disease, CKD) is a worldwide public health problem. According to the epidemiological survey results in different regions, the incidence rate is between 8% and 16%. In my country, about 120 million people suffer from CKD. For decades, although people have extensively explored the pathogenesis and intervention strategies of CKD, so far, there is still a lack of effective means for the prevention and treatment of chronic kidney disease. A considerable number of CKD patients eventually develop into end-stage renal disease, requiring expensive Renal replacement therapy brings a great burden to families and society. Although the etiology of chronic kidney disease is complex, the ultimate common pathologica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4439A61P13/12
CPCA61K31/4439A61P13/12
Inventor 游然贾占军张玥张爱华杨运文于晓文李延伟周维
Owner NANJING CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com